Assessing the Effectiveness of Sanofi Pasteur’s Dengue Vaccine (Dengvaxia) Against Hospitalization and Symptomatic Infection in the State of Parana – Brazil

Overview

The study seeks to assess the effectiveness of Sanofi Pasteur´s dengue vaccine (Dengvaxia®) according to the age, dose and municipality of residence in five municipalities of Paraná State. Specific objectives include: – To assess the effectiveness of Dengvaxia® in preventing dengue hospitalization and dengue symptomatic cases. – To assess the effectiveness of Dengvaxia® in preventing dengue hospitalization and dengue symptomatic cases according in the following age groups 15 to 18 and 19 to 27 years of age in the municipalities of Maringá, Foz de Iguaçu, Londrina, Sarandi and Paranaguá. – To assess the effectiveness of Dengvaxia® in preventing dengue hospitalization and dengue symptomatic cases in the following age groups 9 to 14 and 28 to 45 years of age in the municipality of Paranaguá.

Full Title of Study: “Assessing the Effectiveness of Sanofi Pasteur’s Dengue Vaccine (Dengvaxia) Against Hospitalization and Symptomatic Infection in the State of Parana – Brazil”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: March 1, 2020

Detailed Description

The effectiveness of Sanofi Pasteur´s dengue vaccine (Dengvaxia®) according to the age will be assessed in five municipalities of Paraná State – Maringá, Foz de Iguaçu, Londrina, Sarandi and Paranaguá. Any health service located in each of the five municipalities may report a suspected dengue case. However, in all five municipalities, there is a large public emergency service, the UPA. There are currently three UPA in Londrina, two in Maringá and Foz do Iguaҫu and one each in Paranaguá and Sarandi. These facilities are responsible for reporting the majority of suspected dengue cases. In Londrina and Maringá, the private health sector also provides emergency care. The implementation of the study protocol adds a collection of a blood sample for PCR to the existing protocol for addressing suspected dengue cases among individuals within the target vaccination age groups. The study will count on the activities already carried out by teams of epidemiological surveillance of dengue intensifying the identification of the serotype through the laboratory method RT-PCR (Reverse Transcription Polymerase Chain Reaction) in real time. In addition, the investigators will identify hospitals and health units that attend dengue cases for sample collection, to perform real-time RT-PCR and initial processing of the blood samples collected from the controls.

Interventions

  • Biological: CYD-TDV
    • Dengue vaccine

Arms, Groups and Cohorts

  • Hospitalized and controls
    • Age-matched case of hospitalized dengue and non-dengue control
  • Outpatient and controls
    • Age-matched dengue case and non-dengue control

Clinical Trial Outcome Measures

Primary Measures

  • Dengue symptomatic case
    • Time Frame: Aug 2017 – March 2020
    • Confirmed (by PCR) case of dengue fever

Secondary Measures

  • Dengue hospitalization
    • Time Frame: Aug 2017 – March 2020
    • Hospitalization for severe dengue fever

Participating in This Clinical Trial

Inclusion criteria for cases:

  • Individuals living in the municipalities of Sarandi, Paranaguá, Londrina, Maringá or Foz de Iguaçu in the three stages of vaccination – Individuals with ages ranging from 9 to 44 years for the municipality of Paranaguá and 15 to 27 years for the municipalities of Sarandi, Londrina, Maringá and Foz de Iguaçu – All participants who are 18 years of age or older sign the informed consent form – All minors under the age of 18 who sign the consent form and have the consent form signed by a guardian for the minor – Case with virological isolation of one of the dengue viruses Case exclusion criteria:

• Those who have been deprived of their liberty (jails, penitentiaries, drug addicts, etc.) within 15 days before the onset of signs and symptoms Inclusion criteria for controls:

  • Individuals without symptoms for dengue in the 15 days prior to the onset of symptoms of the case – IgM negative for dengue – Individuals living in the municipalities of Paranaguá, Londrina, Maringá, Sarandi or Foz de Iguaçu in the three stages of vaccination – Belongs to the same age group as case – Participants aged between 9 and 44 years for the municipality of Paranaguá – Participants 15 to 27 years for the municipalities of Maringá, Foz de Iguaçu, Londrina and Sarandi – Resides in the same neighborhood as the case, study at the same institution as the case or work in the same company as the case for at least 15 days before the onset of the case symptoms – Participants that are 18 years of age or older and who sign the informed consent form – All minors under the age of 18 who sign the consent form and have the consent form signed by a guardian for the minor

Gender Eligibility: All

Minimum Age: 9 Years

Maximum Age: 44 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Albert B. Sabin Vaccine Institute
  • Collaborator
    • Pan American Health Organization
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Denise O Garrett, MD, MSc, Study Director, Albert B. Sabin Vaccine Institute

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.